1411 related articles for article (PubMed ID: 27548033)
21. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
22. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
24. Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells.
Tanimoto K; Muranski P; Miner S; Fujiwara H; Kajigaya S; Keyvanfar K; Hensel N; Barrett AJ; Melenhorst JJ
Cytotherapy; 2014 Jan; 16(1):135-46. PubMed ID: 24176543
[TBL] [Abstract][Full Text] [Related]
25. A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.
Hasan AN; Kollen WJ; Trivedi D; Selvakumar A; Dupont B; Sadelain M; O'Reilly RJ
J Immunol; 2009 Aug; 183(4):2837-50. PubMed ID: 19635907
[TBL] [Abstract][Full Text] [Related]
26. Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy.
Foster AE; Gottlieb DJ; Marangolo M; Bartlett A; Li YC; Barton GW; Romagnoli JA; Bradstock KF
J Hematother Stem Cell Res; 2003 Feb; 12(1):93-105. PubMed ID: 12662440
[TBL] [Abstract][Full Text] [Related]
27. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.
Imahashi N; Nishida T; Ito Y; Kawada J; Nakazawa Y; Toji S; Suzuki S; Terakura S; Kato T; Murata M; Naoe T
Mol Immunol; 2013 Dec; 56(4):399-405. PubMed ID: 23911395
[TBL] [Abstract][Full Text] [Related]
29. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes.
Masuoka M; Yoshimuta T; Hamada M; Okamoto M; Fumimori T; Honda J; Oizumi K; Itoh K
Viral Immunol; 2001; 14(4):369-77. PubMed ID: 11792066
[TBL] [Abstract][Full Text] [Related]
30. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
[TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
32. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens.
Tabi Z; Moutaftsi M; Borysiewicz LK
J Immunol; 2001 May; 166(9):5695-703. PubMed ID: 11313411
[TBL] [Abstract][Full Text] [Related]
33. CD80 Expressed by CD8
Rollins MR; Gibbons Johnson RM
J Immunol Res; 2017; 2017():7659462. PubMed ID: 29181416
[TBL] [Abstract][Full Text] [Related]
34. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
[TBL] [Abstract][Full Text] [Related]
35. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
[TBL] [Abstract][Full Text] [Related]
36. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
Abu-Khader A; Krause S
Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
[TBL] [Abstract][Full Text] [Related]
37. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
[TBL] [Abstract][Full Text] [Related]
38. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.
Hofmeyer KA; Jeon H; Zang X
J Biomed Biotechnol; 2011; 2011():451694. PubMed ID: 21960736
[TBL] [Abstract][Full Text] [Related]
39. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
40. Use of Engineered Exosomes Expressing HLA and Costimulatory Molecules to Generate Antigen-specific CD8+ T Cells for Adoptive Cell Therapy.
Kim S; Sohn HJ; Lee HJ; Sohn DH; Hyun SJ; Cho HI; Kim TG
J Immunother; 2017 Apr; 40(3):83-93. PubMed ID: 28099196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
